Pleasanton, CA, United States of America

Mary K Warren


Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 70(Granted Patents)


Location History:

  • San Leandro, CA (US) (1989)
  • Pleasanton, CA (US) (1992)

Company Filing History:


Years Active: 1989-1992

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mary K Warren: Innovator in Recombinant Technology

Introduction

Mary K Warren is a notable inventor based in Pleasanton, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of recombinant colony stimulating factors. With a total of 2 patents, her work has implications for overcoming immunosuppression caused by chemotherapy and other factors.

Latest Patents

Mary K Warren's latest patents focus on the uses of recombinant colony stimulating factor-1. This lymphokine, CSF-1, is crucial in addressing immunosuppression. It is obtained in usable amounts through recombinant methods, which include cloning and expression of both murine and human DNA sequences encoding this protein. Additionally, her patents cover DNA encoding for CSF-1 and the accompanying recombinant systems, further emphasizing the importance of this protein in medical applications.

Career Highlights

Mary K Warren has had a distinguished career, working at Cetus Corporation, where she has been able to apply her innovative ideas in a collaborative environment. Her research has contributed to advancements in biotechnology and has the potential to improve patient outcomes in various medical treatments.

Collaborations

Some of her notable coworkers include Peter Ralph and Ernest S Kaswasaki. Their collaboration has likely fostered an environment of innovation and creativity, leading to significant advancements in their field.

Conclusion

Mary K Warren's contributions to recombinant technology and her innovative patents highlight her role as a leading inventor in biotechnology. Her work continues to influence the medical field and offers hope for improved treatments for immunosuppressed patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…